Discovery of Selective and Potent Macrocyclic CDK9 Inhibitors for the Treatment of Osimertinib-Resistant Non-Small-Cell Lung Cancer.
Wu T, Yu B, Xu Y, Du Z, Zhang Z, Wang Y, Chen H, Zhang LA, Chen R, Ma F, Gong W, Yu S, Qiu Z, Wu H, Xu X, Wang J, Li Z, Bian J.
Wu T, et al. Among authors: chen r, chen h.
J Med Chem. 2023 Nov 23;66(22):15340-15361. doi: 10.1021/acs.jmedchem.3c01400. Epub 2023 Oct 23.
J Med Chem. 2023.
PMID: 37870244